Drugmaker Bristol-Myers Squibb is warning against the use of the
antibiotic drug Tequin in diabetic patients after reports of several
fatalities, the U.S. Food and Drug Administration said on Thursday.
The company is adding a contraindication warning for people with diabetes
to the drug's label as well as strengthening its warning that Tequin can
cause both low and high blood glucose levels in patients, the FDA said.
The label will include warnings that patients who are older, have renal
insufficiency and take other medicine that affects glucose levels can also
be at risk, according to the agency.
"The FDA will continue monitoring Tequin's safety to ensure that its
benefits outweigh the risks to patients," the FDA said in a statement.
Bristol-Myers spokesman Eric Miller said the company's warning was
prompted by reports of "serious cases" of high or low blood glucose among
Tequin patients.
Learn more>>
antibiotic drug Tequin in diabetic patients after reports of several
fatalities, the U.S. Food and Drug Administration said on Thursday.
The company is adding a contraindication warning for people with diabetes
to the drug's label as well as strengthening its warning that Tequin can
cause both low and high blood glucose levels in patients, the FDA said.
The label will include warnings that patients who are older, have renal
insufficiency and take other medicine that affects glucose levels can also
be at risk, according to the agency.
"The FDA will continue monitoring Tequin's safety to ensure that its
benefits outweigh the risks to patients," the FDA said in a statement.
Bristol-Myers spokesman Eric Miller said the company's warning was
prompted by reports of "serious cases" of high or low blood glucose among
Tequin patients.
Learn more>>
No comments:
Post a Comment